Sanofi-aventis Groupe announced the acquisition of Translate Bio to expand its portfolio in the production of therapeutics.
Merck & Co., Inc. introduced three new products to support the flexible manufacturing of biologics, including first-of-its-kind single-use tangential flow filtration capsules for the bioprocessing of antibody-drug conjugates and monoclonal antibodies.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 3462
Published Date: May 02, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The increasing spending in the field of protein chemistry, immunology, molecular biology, biochemistry, and microbiology are the major factors driving the market growth.
The market size of vertebrobasilar artery syndrome treatment is anticipated to attain a CAGR of 2% over the forecast period, i.e., 2023-2035.
Lack of health awareness amongst people are estimated to be the growth hindering factors for the market expansion.
The market in the Asia Pacific region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
The major players in the market are Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., Baxter International, Inc., Novartis AG, Sanofi-aventis Groupe, AbbVie Inc., Pfizer Inc., and other key players.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by diagnosis, treatment, distribution channel, and by region.
The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.